Provided is a polypeptide including an amino acid sequence represented by any of SEQ ID NOs:13-24, or a sequence having at least 90% sequence homology with any one of the foregoing, or a sequence having at least 95% sequence homology with any one of the foregoing. Also provided is a polynucleotide including a fluorescent protein connected to an aequorin by a linker, wherein the amino acid sequence of the fluorescent protein is represented by amino acids 1 through 239 of SEQ ID NO:13, amino acids 1 through 239 of SEQ ID NO:14, amino acids 1 through 237 of SEQ ID NO:15, or amino acids 1 through 237 of SEQ ID NO:16, the amino acid sequence of the linker is represented by amino acids 240 through 256 of SEQ ID NO:13, and the amino acid sequence of the aequorin is represented by amino acids 257 through 448 of SEQ ID NO:13, amino acids 257 through 450 of SEQ ID NO:17, or amino acids 257 through 450 of SEQ ID NO:21. Also provided is a polynucleotide including a sequence that encodes for the polypeptide and a viral vector including the polynucleotide.

Provided is a method of detecting neural activity, including inducing neurons of a subject to express two or more polypeptides each comprising an amino acid sequence represented by one of SEQ ID NOs:13-24, wherein inducing comprises stimulating interneuronally different relative levels of expression of the two or more polypeptides; applying coelenterazine to the subject; applying a first stimulation of neural activity to the subject; detecting a first spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the first stimulation; recording the first spatiotemporal and spectral pattern of electromagnetic radiation in a computer memory; applying a second stimulation of neural activity to the subject; detecting a second spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the second stimulation; comparing the second spatiotemporal and spectral pattern of electromagnetic radiation to the first spatiotemporal and spectral pattern of electromagnetic radiation, wherein differences between the second spatiotemporal and spectral pattern of electromagnetic radiation and the first spatiotemporal and spectral pattern of electromagnetic radiation indicate differences in neural activity caused by the first stimulation and the second stimulation.

Provided is a method of detecting neural activity, including inducing neurons of a subject to express two or more polypeptides each comprising an amino acid sequence represented by one of SEQ ID NOs:13-24, wherein inducing comprises stimulating interneuronally different relative levels of expression of the two or more polypeptides; applying coelenterazine to the subject; applying a first stimulation of neural activity to the subject; detecting a first spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the first stimulation; recording the first spatiotemporal and spectral pattern of electromagnetic radiation in a computer memory; applying a second stimulation of neural activity to the subject; detecting a second spatiotemporal and spectral pattern of electromagnetic radiation emitted by neurons of the subject in response to the second stimulation; comparing the second spatiotemporal and spectral pattern of electromagnetic radiation to the first spatiotemporal and spectral pattern of electromagnetic radiation, wherein differences between the second spatiotemporal and spectral pattern of electromagnetic radiation and the first spatiotemporal and spectral pattern of electromagnetic radiation indicate differences in neural activity caused by the first stimulation and the second stimulation.

The invention relates to vectors based on a virus from the order Mononegavirales, and in particular a rabies virus. More specifically, it relates to a rabies virus vector which, having transfected a target cell, is switchable between replication-competent and replication-incompetent forms. Amongst other applications, the invention avoids the cytotoxicity associated with current vectors based on rabies virus.

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD47, and methods of use thereof.

The present invention relates to a method for culturing a 3-dimensional lung cancer organoid and a method for preparing a patient-derived xenograft animal model using the same. More specifically, the present invention relates to a method for culturing a 3-dimensional lung cancer organoid, a lung cancer organoid prepared by the method, a medium composition for culturing the lung cancer organoid, a method for preparing a xenograft animal model using the lung cancer organoid, a patient-derived lung cancer organoid xenograft animal model prepared by the method, and a method for analyzing therapeutic efficacy of an anticancer agent and a method for screening an anticancer agent, using the animal model.

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) SIRPα, and methods of use thereof.

This disclosure relates to a genetically modified rodent and use thereof as a rodent model. More specifically, this disclosure relates to rodent (e.g., mouse or rat) comprising a loss of function mutation in an endogenous Crnn (cornulin) gene, and to use of such a rodent animal as a rodent model of skin inflammation disorders (e.g., psoriasis),

Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.

One variation of a method for producing a target compound includes: during an initial period, genetically modifying a population of insects to produce a target compound; during a growth period succeeding the initial period, cultivating the population of insects; during a treatment period succeeding the growth period, applying a dosage of a stressor to the population of insects, the stressor configured to trigger production of the target compound; in response to a proportion of the target compound within the population of insects exceeding a threshold proportion, harvesting the population of insects; homogenizing the population of insects to form a blend comprising the proportion of the target compound and a second proportion of a set of secondary components; and separating the proportion of the target compound from the second proportion of the set of secondary components for extraction of the proportion of the target compound from the blend.